Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.44M Sell
33,892
-18,818
-36% -$1.77M 0.02% 617
2026
Q1
$6.23M Buy
52,710
+2,147
+4% +$265K 0.05% 294
2025
Q4
$6.36M Sell
50,563
-2,658
-5% -$347K 0.06% 266
2025
Q3
$7.79M Buy
53,221
+6,358
+14% +$961K 0.07% 229
2025
Q2
$7.31M Sell
46,863
-34,278
-42% -$5.44M 0.08% 207
2025
Q1
$13.4M Buy
81,141
+46,659
+135% +$7.76M 0.2% 100
2024
Q4
$5.62M Buy
34,482
+1,564
+5% +$280K 0.1% 192
2024
Q3
$6.43M Sell
32,918
-5,096
-13% -$939K 0.16% 123
2024
Q2
$6.59M Sell
38,014
-499
-1% -$83K 0.18% 111
2024
Q1
$6.52M Sell
38,513
-1,757
-4% -$329K 0.14% 185
2023
Q4
$7.95M Buy
40,270
+5,128
+15% +$908K 0.2% 153
2023
Q3
$6.11M Buy
+35,142
New +$6.38M 0.19% 151

Other funds holding ZTS

Vident Advisory's ZTS Position: Q2 2026 in Review

Vident Advisory reduced its Zoetis (ZTS) stake by 36% in Q2 2026, selling an estimated $1.77M and leaving 33,892 shares worth $2.44M. The position accounts for 0.02% of the portfolio, ranked #617.

Vident Advisory first reported a position in ZTS in Q3 2023 and has held it in 12 quarters since. The position peaked at $13.4M in Q1 2025. 1,435 funds tracked by Wall St. Rank hold ZTS as of Q2 2026.

  • Vident Advisory held 33,892 shares of Zoetis worth $2.44M as of Q2 2026.
  • Vident Advisory sold 18,818 Zoetis shares in Q2 2026, an estimated $1.77M.
  • Zoetis made up 0.02% of Vident Advisory's portfolio in Q2 2026, its #617 holding.
  • Vident Advisory first reported a position in Zoetis in Q3 2023 and has held it in 12 quarters since.
  • Vident Advisory's Zoetis position peaked at $13.4M in Q1 2025.
  • 1,435 funds tracked by Wall St. Rank held Zoetis as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.